Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development
Pharmaceutical Technology
OCTOBER 6, 2022
Intended for intranasal administration, NGoXIM was demonstrated to be effective in animal models and elicited a durable and cross-protective immune response in proof-of-concept (PoC) studies. . A sexually transmitted disease, gonorrhoea is caused by the NG bacteria.
Let's personalize your content